Scancell Holdings plc (LON:SCLP - Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 9.79 ($0.13) and traded as low as GBX 9.75 ($0.13). Scancell shares last traded at GBX 9.86 ($0.13), with a volume of 2,288,309 shares traded.
Scancell Trading Up 0.5%
The firm has a 50-day moving average of GBX 9.96 and a 200-day moving average of GBX 9.79. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The firm has a market capitalization of £101.70 million, a P/E ratio of -777.78 and a beta of 0.35.
Scancell (LON:SCLP - Get Free Report) last posted its quarterly earnings results on Thursday, September 11th. The company reported GBX (1.26) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.
Insiders Place Their Bets
In other Scancell news, insider Martin Diggle acquired 3,150,000 shares of the company's stock in a transaction on Friday, September 12th. The stock was acquired at an average price of GBX 9 per share, for a total transaction of £283,500. In the last three months, insiders purchased 7,652,236 shares of company stock valued at $73,474,596. Company insiders own 15.45% of the company's stock.
Scancell Company Profile
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
